nedaplatin has been researched along with Cystadenocarcinoma, Serous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, H; Han, Y; Yuan, L | 1 |
| Eastman, A; Hom, DK; Howell, SB; Isonishi, S | 1 |
2 other study(ies) available for nedaplatin and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Comparisons of the survival time of patients with ovarian cancer adopting post-operative chemotherapy by use of paclitaxel combined with carboplatin or nedaplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Postoperative Care; Prognosis; Survival Rate | 2016 |
Enhancement of sensitivity to platinum(II)-containing drugs by 12-O-tetradecanoyl-phorbol-13-acetate in a human ovarian carcinoma cell line.
Topics: Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; DNA, Neoplasm; Drug Synergism; Enzyme Activation; Female; Glutathione; Glutathione Transferase; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Protein Kinase C; Pyrazoles; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1994 |